March 13th Options Now Available For Cardinal Health (CAH)

Cardinal Health (CAH) is the subject of an options trade idea: a $210 put is bid at $5.00, which nets a $205 cost basis if sold-to-open and is ~2% out-of-the-money versus the $213.32 stock price, with a 59% probability of expiring worthless and a 2.38% cash-return (20.23% annualized). On the call side, a $215 call is bid at $6.20 for a covered-call sold against shares at $213.32, representing a potential 3.69% total return if called at the March 13 expiration, a 50% odds of expiring worthless, and a 2.91% immediate boost (24.69% annualized). Implied volatilities are ~30% (put) and 29% (call) versus a trailing 12-month volatility of 27%.

Analysis

Market structure: short-dated option sellers and income-oriented retail/institutional accounts are the direct winners here — they can lock in a 2.38%–2.91% return to Mar 13 (annualized 20%–25%) by selling cash‑secured puts or covered calls on CAH. Dealers and exchanges (NDAQ) pick up fee/flow benefits; long-only holders face assignment risk and capped upside if covered calls are used. The small IV premium (29%–30% vs realized 27%) signals modest demand for downside protection but not panic — sellers still get a positive edge if realized stays near historical levels.

Risk assessment: tail risks include regulatory probes into distribution/reimbursement, a large customer contract loss, or a surprise earnings miss that drives >10–15% gap moves — any such event would blow past short‑dated option sellers. Immediate horizon (days to Mar 13) is dominated by gamma/assignment risk and IV movements; weeks–months hinge on earnings and Pharma partner news; long term (quarters) depends on execution and margin trends. Hidden risks: early assignment, liquidity/commission drag, and capital usage for cash‑secured positions; key catalysts are quarterly results, major pharma supply announcements, and sector M&A chatter.

Trade implications: for tactical income, sell-to-open CAH Mar13 $210 cash‑secured puts to collect ~$5 (effective basis $205) sized 1–2% portfolio; alternatively, if already long CAH, sell Mar13 $215 covered calls for ~$6.20 to harvest 2.9% while capping upside. To limit tail exposure, prefer put credit spreads (sell $210 / buy $200) or sell spreads only if IV ≥ current 29%–30%; trim or hedge if CAH falls >5% intraday or IV rises >8 vol points.

Contrarian angle: the headline annualized yields overstate true return because duration is short — repeated roll risk and occasional >8% realized moves can wipe out several cycles of premium. Market is underpricing assignment/friction costs and overpricing wraparound convenience (easy yield). Historical distributor shocks (reimbursement shocks) have produced >15% moves; plan for that by using defined‑risk spreads rather than naked short puts if managing >2% position sizes.

Key Decisions for Investors

• Establish a tactical cash‑secured put position: sell-to-open CAH Mar13 $210 puts (collect ≈ $5) sized to 1–2% of portfolio for an effective entry at $205; use this if you are willing to own CAH at $205 and set a hard stop to hedge or close if CAH < $195 within 10 trading days or IV > +8 vol points.
• If already long CAH, sell Mar13 $215 covered calls (collect ≈ $6.20) to lock a 3.7% return to expiry; roll out or lift the call if CAH rallies >5% or ahead of any company/sector catalyst (earnings, material Pharma contract news).
• Prefer defined‑risk option spreads over naked short puts for >2% position sizes: sell CAH Mar13 $210 / buy $200 put spread (max loss defined) to collect most premium while capping tail risk; execute if net credit ≥ $3.50.
• Monitor three triggers before increasing exposure: (1) IV term structure — buy‑write/put‑sell only if 30d IV ≥ 28% and 90d IV ≤ 32%, (2) fundamental news — avoid new sells within 5 trading days of earnings or major Pharma announcements, (3) price action — pause selling if CAH declines >5% in a session or daily volume spikes >2x average.
• Avoid directional large longs in the distributor group; consider small long CAH via covered‑income (above) while shorting a broader healthcare distributor peer or ETF only if relative fundamentals diverge by >10% P/E or margin expectation (use this as a hedge, not a primary return driver).